Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report) saw a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 25,783 shares, a growth of 92.0% from the October 15th total of 13,429 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 18,220 shares, the short-interest ratio is presently 1.4 days.
Pharming Group Stock Down 0.1%
Shares of PHAR stock traded down $0.01 during mid-day trading on Monday, hitting $12.59. The company’s stock had a trading volume of 10,483 shares, compared to its average volume of 20,007. Pharming Group has a 52-week low of $9.11 and a 52-week high of $21.34. The business has a 50-day moving average price of $10.96 and a 200 day moving average price of $13.48. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.65 and a current ratio of 3.23. The stock has a market cap of $891.10 million, a price-to-earnings ratio of 39.34 and a beta of -0.05.
Pharming Group (NASDAQ:PHAR – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. Pharming Group had a return on equity of 8.70% and a net margin of 6.23%. The firm had revenue of $117.60 million for the quarter, compared to the consensus estimate of $117.60 million. Research analysts predict that Pharming Group will post 0.34 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
PHAR has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Tuesday, September 22nd. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a report on Wednesday, October 28th. Weiss Ratings raised Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, November 11th. Wall Street Zen upgraded Pharming Group from a “hold” rating to a “strong-buy” rating in a report on Sunday, November 1st. Finally, Canaccord Genuity Group lifted their price target on Pharming Group from $38.00 to $41.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Three investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.67.
Get Our Latest Stock Analysis on PHAR
Hedge Funds Weigh In On Pharming Group
A hedge fund recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP purchased a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group accounts for 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned 3.03% of Pharming Group as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 0.03% of the company’s stock.
Pharming Group Company Profile
Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
See Also
- Five stocks we like better than Pharming Group
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
